HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock

HeartBeam system was recently cleared by the U.S. Food and Drug Administration (FDA) for comprehensive arrhythmia assessment 510(k) application submitted to the FDA for the Company's groundbreaking 12-lead